Drugs /

pf-07284890

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for pf-07284890

Pf-07284890 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating pf-07284890, 1 is phase 1 (1 open).

BRAF Codon 600 Missense is the most frequent biomarker inclusion criterion for pf-07284890 clinical trials.

Malignant solid tumor and primary brain neoplasm are the most common diseases being investigated in pf-07284890 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pf-07284890
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pf-07284890 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
arry-461
Drug Target(s) [2]:
BRAF

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.